{"id":390526,"date":"2018-12-14T00:00:00","date_gmt":"2018-12-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0003-2018-biopharma-non-alcoholic-steatohepatitis-nash-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:36","modified_gmt":"2026-03-31T10:47:36","slug":"dlsfmd0003-2018-biopharma-non-alcoholic-steatohepatitis-nash-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0003-2018-biopharma-non-alcoholic-steatohepatitis-nash-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Non-Alcoholic Steatohepatitis (NASH) | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"

Nonalcoholic steatohepatitis (NASH<\/abbr>) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the prevalence of the disease. The body of evidence for the financial costs of the disease is growing, particularly with respect to cardiovascular (CV)<\/abbr>\u00a0disease, liver failure, and the fact that\u00a0NASH<\/abbr>\u00a0will quickly become the leading reason for liver transplantation. The lack of treatment options and the limited awareness of the disease and its complications haveresulted in low diagnosis and treatment rates. However, as education increases, novel diagnostic tools are developed, and new therapies are approved, diagnosis and treatment rates will increase, driving growth of the market overall. Currently, only off-label medications are available for NASH; they will sustain the small market over the first half of the 2017-2027 forecast period, until the anticipated approval and launch of the first wave of emerging therapies: Intercept Pharmaceutical\u2019s obeticholic acid, Gilead\u2019s selonsertib, Genfit\u2019s elafibranor, and Allergan\u2019s cenicriviroc. We anticipate gradual uptake of the new therapies, but if and when their long-term safety, liver-related benefits, and reductions in mortality are demonstrated later in the forecast period, their uptake will accelerate. These novel therapies will be able to command high prices owing to the innovation they provide for an indication without pharmacotherapeutic options. However, pricing strategies must take into account payers\u2019 budgets and patients\u2019 compliance owing to the relatively slow natural history of\u00a0NASH<\/abbr>\u00a0and the need for long-term treatment.<\/p>\n

Questions Answ<\/strong>ered:<\/strong><\/p>\n